Connexin (Gap Junction Protein) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Connexin (Gap Junction Protein) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Connexin (Gap Junction Protein) - Pipeline Review, H2 2016', provides in depth analysis on Connexin (Gap Junction Protein) targeted pipeline therapeutics. 

The report provides comprehensive information on the Connexin (Gap Junction Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connexin (Gap Junction Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Connexin (Gap Junction Protein) 
- The report reviews Connexin (Gap Junction Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Connexin (Gap Junction Protein) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Connexin (Gap Junction Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Connexin (Gap Junction Protein) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Connexin (Gap Junction Protein) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Connexin (Gap Junction Protein) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Connexin (Gap Junction Protein) Overview 6
Therapeutics Development 7
Connexin (Gap Junction Protein) - Products under Development by Stage of Development 7
Connexin (Gap Junction Protein) - Products under Development by Therapy Area 8
Connexin (Gap Junction Protein) - Products under Development by Indication 9
Connexin (Gap Junction Protein) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Connexin (Gap Junction Protein) - Products under Development by Companies 12
Connexin (Gap Junction Protein) - Products under Development by Universities/Institutes 14
Connexin (Gap Junction Protein) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Connexin (Gap Junction Protein) - Companies Involved in Therapeutics Development 23
Theranexus SAS 23
Vichem Chemie Research Ltd. 24
Connexin (Gap Junction Protein) - Drug Profiles 25
(flecainide acetate + modafinil) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CODA-001 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
JM-2 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
THN-01 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
VID-45110 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Connexin (Gap Junction Protein) - Dormant Projects 33
Connexin (Gap Junction Protein) - Discontinued Products 35
Connexin (Gap Junction Protein) - Featured News & Press Releases 36
May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness 36
Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 37
Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA) 37
Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 38
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 39
May 25, 2010: CoDa Therapeutics Achieves Positive Results From Phase II Efficacy Study Of NEXAGON In Chronic Venous Leg Ulcers 39
May 11, 2009: CoDa Therapeutics Receives Orphan Drug Designation For Nexagon For The Treatment Of Persistent Corneal Epithelial Defects 40

Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Theranexus SAS, H2 2016 23
Pipeline by Vichem Chemie Research Ltd., H2 2016 24
Dormant Projects, H2 2016 33
Dormant Projects (Contd..1), H2 2016 34
Discontinued Products, H2 2016 35